URGN (UroGen Pharma) E10: $-4.55 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

URGN UroGen Pharma Ltd URGN
69 GF Score
Price $44.08
GF Value $27.86
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is UroGen Pharma E10?

UroGen Pharma URGN -1.85% 69 E10 is $-4.55 as of Jun. 2026. GuruFocus rates URGN with a GF Score™ of 69/100 and a GF Value™ of $27.86 (Significantly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

UroGen Pharma's adjusted earnings per share data for the three months ended in Jun. 2026 was $-0.280. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-4.55 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-09-07), UroGen Pharma's current stock price is $44.08. UroGen Pharma's E10 for the quarter that ended in Jun. 2026 was $-4.55. UroGen Pharma's Shiller PE Ratio of today is .


UroGen Pharma  (NAS:URGN) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


UroGen Pharma E10 Related Terms


UroGen Pharma E10 Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma E10 Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -4.50

UroGen Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -4.50 -4.51 -4.55

URGN vs PVLA, KLRA, VCEL: E10 Comparison

For the Biotechnology subindustry, UroGen Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Shiller PE Ratio falls into.


URGN
69GF Score
UroGen Pharma Ltd URGN
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, UroGen Pharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.28/333.9520*333.9520
=-0.280

Current CPI (Jun. 2026) = 333.9520.

UroGen Pharma Quarterly Data

per share eps CPI Adj_EPS
201609 -0.718 241.428 -0.993
201612 1.027 241.432 1.421
201703 -0.367 243.801 -0.503
201706 -0.700 244.955 -0.954
201709 -0.020 246.819 -0.027
201712 -0.740 246.524 -1.002
201803 -0.880 249.554 -1.178
201806 -1.140 251.989 -1.511
201809 -1.280 252.439 -1.693
201812 -1.460 251.233 -1.941
201903 -1.110 254.202 -1.458
201906 -1.080 256.143 -1.408
201909 -1.060 256.759 -1.379
201912 -1.870 256.974 -2.430
202003 -1.790 258.115 -2.316
202006 -1.440 257.797 -1.865
202009 -1.310 260.280 -1.681
202012 -1.380 260.474 -1.769
202103 -1.170 264.877 -1.475
202106 -1.170 271.696 -1.438
202109 -1.350 274.310 -1.644
202112 -1.270 278.802 -1.521
202203 -1.250 287.504 -1.452
202206 -1.180 296.311 -1.330
202209 -1.130 296.808 -1.271
202212 -1.220 296.797 -1.373
202303 -1.300 301.836 -1.438
202306 -1.030 305.109 -1.127
202309 -0.680 307.789 -0.738
202312 -0.660 306.746 -0.719
202403 -0.870 312.332 -0.930
202406 -0.820 314.175 -0.872
202409 -0.510 315.301 -0.540
202412 -0.800 315.605 -0.847
202503 -0.920 319.799 -0.961
202506 -1.050 322.561 -1.087
202509 -0.690 324.800 -0.709
202512 -0.540 324.054 -0.556
202603 -0.470 330.213 -0.475
202606 -0.280 333.952 -0.280

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-4.55 mean?
UroGen Pharma (URGN) has a E10 of $-4.55 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on UroGen Pharma and its competitors.
Is UroGen Pharma's E10 too high?
UroGen Pharma's current E10 is $-4.55. Overall, UroGen Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's E10 compare to PVLA and KLRA?
UroGen Pharma's E10 of $-4.55 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current E10 is $-4.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (URGN) is currently considered Significantly Overvalued. The stock's GF Value™ is $27.86, compared to a current price of $44.08 — trading 58.2% above its estimated fair value. The current E10 is $-4.55. UroGen Pharma's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For UroGen Pharma (URGN), the current E10 is $-4.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (URGN) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of $44.08 is trading 58.2% above its estimated GF Value™ of $27.86. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for URGN:

  • E10: $-4.55
  • GF Value™: $27.86 vs. price of $44.08 (58.2% above fair value)
  • GF Score™: 69/100 with 9 warning signs

No single metric tells the full story. See the URGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UroGen Pharma Business Description

Other Exchanges 0XOD:UKUR8:Germany
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
69GF Score

Get the complete analysis for URGN

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.08
Price
$27.86
GF Value